Articles

Favorable efficacy and manageable safety are shown in the updated analysis of the phase 1 study of teclistamab in patients with relapsed/refractory multiple myeloma (RRMM). This analysis supports the planned phase 2 monotherapy trial at 1500 µg/kg administered subcutaneously. Read More ›

This phase 1, first-in-human study evaluates patients with relapsed/refractory multiple myeloma (RRMM) who are heavily pretreated with REGN5458. Results of this updated analysis are consistent with those of previous findings showing an acceptable safety profile and deep and durable responses. The phase 2 portion of the study is further progressing. Read More ›

This primary analysis evaluated patients with relapsed/refractory multiple myeloma (RRMM) who had received ≥1 prior lines of therapy, including lenalidomide (Len) and a proteasome inhibitor (PI). Compared with pomalidomide and dexamethasone (Pd) alone, daratumumab (DARA) plus Pd reduced the risk of disease progression and death without additional safety signals. Read More ›

Patients who were non–transplant eligible, newly diagnosed with multiple myeloma (NDMM) and frail have inferior overall survival (OS), primarily because of treatment discontinuation due to toxicity. Therefore, evaluation of less-toxic effective therapies, such as the oral proteasome inhibitor ixazomib (Ixa) and the monoclonal anti-CD38 antibody daratumumab (Dara), is critical for this patient population as well as the elderly. Read More ›

The CANDOR trial was a randomized, open-label, phase 3 study in which carfilzomib, dexamethasone, and daratumumab were compared with carfilzomib and dexamethasone (Kd) for the treatment of patients with relapsed/refractory multiple myeloma (RRMM) who had undergone 1 to 3 prior lines of therapy. Read More ›

In patients with relapsed/refractory multiple myeloma (RRMM), although promising efficacy and acceptable toxicity were reported for belantamab mafodotin plus pomalidomide and dexamethasone, the high dose rate holds at the 2.5-mg/kg dose level were deemed to warrant examination of alternative-dosing schedules. Read More ›

Because multiple myeloma is a progressive disease and requires continued successive therapies, and there are few treatment options for patients who are refractory to anti-CD38 monoclonal antibodies, new therapies are needed. Read More ›

Results from a phase 3 study of a circularly permuted tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) combined with thalidomide and dexamethasone showed this was a safe and effective treatment for patients with relapsed/refractory multiple myeloma (RRMM), including those with a poor prognosis. Read More ›

The GMMG-HD6 study, an ongoing phase 3, randomized, open-label, multicenter trial, examines the effect of bortezomib, lenalidomide, and dexamethasone (VRD) with or without the addition of elotuzumab as induction therapy for newly diagnosed transplant-eligible patients with multiple myeloma (MM). Read More ›

Patients with light chain (AL) amyloidosis who were previously treated found encouraging efficacy and a good safety profile based on preliminary results from a phase 2 study of isatuximab. Read More ›